Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Berger

Showing results (941-950 of 964) with videos related to

Pageof 97
Sort By:
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Schizophrenia Research|December 13, 2018
Dynamic prediction of transition to psychosis using joint modellingH P Yuen, A Mackinnon, J Hartmann, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Medicine|July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher DiseaseChristine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences|February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease RegistryYann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of the American Academy of Dermatology|May 13, 2014
Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agentsRobert Sidbury, Dawn M Davis, David E Cohen, et al.
Pageof 97

Showing results (941-950 of 964) with videos related to

Sort By:
Pageof 97
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Schizophrenia Research|December 13, 2018
Dynamic prediction of transition to psychosis using joint modellingH P Yuen, A Mackinnon, J Hartmann, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.
Journal of Clinical Medicine|July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher DiseaseChristine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences|February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease RegistryYann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of the American Academy of Dermatology|May 13, 2014
Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agentsRobert Sidbury, Dawn M Davis, David E Cohen, et al.
Pageof 97